The paper systematically varies three scGEM construction factors β preprocessing (raw vs Linnorm+SAVER), MEM (ftINIT, GIMME, iMAT, rFASTCORMICS), and expression threshold (25thβ90th percentile) β yielding 26 strategies evaluated across nine labeled human scRNA-seq datasets with five accuracy metrics, perturbation sensitivity, and computational feasibility . The headline findings are factor-specific: MEM explained the largest variance in gene coverage, task completion, and essential-gene prediction; LS preprocessing most improved clustering; lower thresholds improved completeness metrics while higher thresholds sometimes improved clustering . Notably, clustering performance was strongly dataset-dependent β the best MEM differed across all nine datasets β qualifying any universal recommendation .
The design mirrors bulk-RNA-seq MEM benchmarks but extends them to single-cell sparsity, where findings diverge: lower thresholds outperformed for essential-gene prediction, opposite to the bulk result. The model-size adjustment (linear models regressing out reaction/gene counts) is a genuinely useful methodological contribution, revealing that GIMME's apparent advantage partly reflects larger models, while clustering is largely size-independent . Code is on GitHub and datasets are public GEO/Figshare accessions, supporting reproducibility. The authors are commendably transparent that LS preprocessing is not established as universally optimal β only raw data was the comparator .
Bottom line: a careful, transparently reported, well-powered (for its scope) computational methods benchmark that meaningfully advances scGEM practice via objective-specific guidance. Confidence: moderate β findings are internally consistent and mechanistically plausible, but external validity beyond Human-GEM, two preprocessing options, and human datasets is untested. Falsification would require a comparable benchmark where preprocessing or threshold explains as much variance as MEM, or MEM effects failing to replicate across additional datasets.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.